Meeting
Abstract Number: 129
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Over 6 million people in the US have a diagnosis of atrial fibrillation. Given the increased risk for stroke and systemic embolism, many patients are treated with direct oral anticoagulants (DOACs) to reduce their risk. In the major trials comparing to DOACs to warfarin for stroke and systemic embolism prevention in atrial fibrillation, DOACs […]
Abstract Number: 129
Hospital Medicine 2020, Virtual Competition
Background: Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy. Management of venous thromboembolism (VTE), in these patients, is challenging due to the high risk of recurrence and inherent risk of bleeding in this population. Direct oral anticoagulants (DOACs) have emerged as a treatment options for CAT. As yet there have not been […]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 211
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Hospitalized patients receiving direct oral anticoagulants (DOACs) sometimes require bridging with unfractionated heparin (UFH). Monitoring UFH with anti-Xa assays has been shown to correlate with better outcomes. However, DOACs interfere with anti-Xa assays resulting in inappropriate UFH dose adjustments that can negatively impact patient care. In 2015, we deployed an electronic health record (EHR) […]
Abstract Number: 746
Hospital Medicine 2020, Virtual Competition
Case Presentation: A 46-year-old female presented with a 2-day history of shortness of breath, pleuritic chest pain and lower extremity swelling while taking low-molecular weight heparin (LMWH). One month prior she was diagnosed with a left lower extremity DVT after a hysterectomy. She was treated with LMWH with a planned transition to rivaroxaban. Medical history […]